Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | ANPEP | P15144 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 2/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28785280 | 1.00 | ATM (0.63) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL28305018 | 0.98 | ATM (0.61) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL28305017 | 0.98 | ATM (0.61) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL12666720 | 0.86 | ATM (0.63) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL3725043 | 0.86 | ATM (0.63) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL8724389 | 0.86 | ATM (0.63) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL2734812 | 0.86 | ATM (0.63) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL2602049 | 0.86 | ATM (0.63) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL25432537 | 0.84 | ATM (0.61) | ATMALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL20239092 | 0.84 | ATM (0.61) | ATMALDH1A1THRBCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907546-A | Multifunctional polyurea acid ester derivative and preparation method and application thereof | 四川大学 | 2022-08-16 | — | — | CN | claimed |
| CN-114716635-A | Multifunctional polyurea-amino acid derivative and preparation method and application thereof | 四川大学 | 2022-07-08 | — | — | CN | claimed |
| CN-114907546-A | Multifunctional polyurea acid ester derivative and preparation method and application thereof | 四川大学 | 2022-08-16 | — | — | CN | disclosed |
| CN-114716635-A | Multifunctional polyurea-amino acid derivative and preparation method and application thereof | 四川大学 | 2022-07-08 | — | — | CN | disclosed |
| US-6949570-B2 | Carboxyalkyl substituted sulfonamidomethyl amides or ureas used for treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, and diabetes | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030027850-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ASHWELL SUSAN (US) | 2003-02-06 | — | — | US | disclosed |
| US-6436904-B1 | TREATMENT OF INFLAMMATORY DISEASES IN MAMMALS | ELAN PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | disclosed |
| EP-1150997-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000043415-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027850-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | ATM 3870/4885ALDH1A1 414/4885THRB 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.